Close

Nanoparticle Tiny Tech for Programming T Cells

With over a decade of experience, Creative Biolabs has a comprehensive and unique portfolio to support the discovery and development of one-stop CAR-T therapy. Our cutting-edge technologies, extensive expertise, senior scientists allow us to offer our clients with the most valuable solutions to maximize the success of the projects.

Nanoparticle Tiny Tech for Programming T Cells

CAR-T Cell Therapy: A Revolution

Nanoparticle Tiny Tech for Programming T Cells

Our immune system is critical for the defense against diseases including various infection and cancers. The continuous exploration of the immune system’s mechanisms for fighting cancer has led to the development of different immunotherapies. Now many companies are under research and development to engineer patients’ own T cells with CARs or TCRs to target specific tumor antigens and kill cancer. Upon the approval of CAR-T therapy by the FDA, Commissioner Gottlieb was saying “We’re entering a new frontier in medical innovation with the ability to reprogram a patient’s own cells to attack a deadly cancer.”

Limitations

Although several approved CAR-T therapies have revealed impressive results, the in vitro methods to produce large numbers of CAR-T cells are too elaborate for a broader application to treat patients. Currently, clinical-scale manufacturing of CAR-T cells requires an assortment of elaborate processes including isolating, genetically modifying, selectively expanding, and infusing into the patient. With the requirements of dedicated equipment and considerable expertise, CAR-T therapy can only be provided at a few centers worldwide. The complex procedures and costs involved in producing CAR-T cells are major obstacles for implementing them as standard-of-care in the clinical treatment of cancer.

Our Nanoparticle Tiny Technology

Nanoparticle Tiny Tech for Programming T Cells

To avoid the limitations and complications of traditional CAR-T cell therapy, now Creative Biolabs has developed the cutting-edge tiny technology to program circulating in vivo T cells with tumor antigen specific recognition capabilities. This tiny technology is able to produce CAR-carrying nanoparticles which can target T cells and efficiently introduce CARs into T cell nuclei, thereby leading to long-term cancer cell killing. Our scientists have established an advanced platform to manufacture and produce the nanoparticles in a stable form to create effective CAR-T cells in vitro and in vivo.


Nanoparticle Tiny Tech for Programming T Cells

Fig.1 Design and manufacture of lymphocyte-programming nanoparticles. (Smith, 2017)

The unique advantages of this tiny tech will increase the efficiency and value of your CAR-T therapy project.

  • Stable form
  • Simplify storage
  • Reduce cost
  • Broad application

Highlight Features

  • Nanoparticles can improve economic mileage for CARs;
  • Nanoparticles open an exciting door to CAR-T therapy fighting cancers;
  • Nanoparticles can create effective CAR-T cells in vitro and in vivo which have been validated.

To accelerate your CAR-T therapy innovations, Creative Biolabs offers an end-to-end solution from initial study design, careful execution, accurate data illustration to timely result delivery. Our novel developed nanoparticle tiny technology provides a practical, broadly applicable treatment that can produce anti-tumor efficacy for our clients in a variety of settings. If you are interested in our nanoparticle tech, please feel free to contact us for closer communication to learn how we can be involved in your project.

Reference

  1. Smith, Tyrel T., et al. "In situ programming of leukaemia-specific T cells using synthetic DNA nanocarriers." Nature nanotechnology 12.8 (2017): 813.

Online Inquiry

For any technical issues or products/services related questions, please leave your contacts as below, and our team will contact you at earliest convenience to let you know how we can be involved in your projects.

  • Verification code
    Click image to refresh the verification code.

Key Updates

Receive the latest news and insights to your inbox.